leisure time -WSS

leisure time

author：hotspot 2025-09-29 01:07:32 - browse：44433

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Midwives could help bridge maternal health disparities in the U.S.

hotspot

WSS

Inari Medical to buy amputation prevention company LimFlow

Medicare proceeds with plan to claw back hospital funds

What is microchimerism and how does it affect maternal health?

What happened to the House vote on health price transparency?

What happened to the House vote on health price transparency?

Infant mortality in U.S. rose last year for first time in decades: CDC

leisure time

leisure time

leisure time

Activists slam private health insurers over coverage restrictions

Kidney transplant patients stopped immunosuppressants in trial

Duchenne breakthrough therapy leaves behind pioneering families

Medicare must police algorithms in Medicare Advantage, Dems say

The cancer drug shortage isn’t new — and neither are the solutions

Eli Lilly CEO gives to Mike Pence presidential super PAC

Medicare details structure of new drug price negotiation program

Eli Lilly CEO gives to Mike Pence presidential super PAC

Activists slam private health insurers over coverage restrictions

Inari Medical to buy amputation prevention company LimFlow

focus

Why the quest to eradicate polio has stumbled

Grad students accuse University of California of wage theft

What is microchimerism and how does it affect maternal health?

FDA weighs limits of animal data in assessing artificial wombs

Explaining an after

What happened to the House vote on health price transparency?

focus

hotspot

Wikipedia

focus